Cargando…

Methyl Substitution of a Rexinoid Agonist Improves Potency and Reveals Site of Lipid Toxicity

[Image: see text] (2E,4E,6Z,8E)-8-(3′,4′-Dihydro-1′(2′H)-naphthalen-1′-ylidene)-3,7-dimethyl-2,4,6-octatrienoic acid, 9cUAB30, is a selective rexinoid that displays substantial chemopreventive capacity with little toxicity. 4-Methyl-UAB30, an analogue of 9cUAB30, is a potent RXR agonist but caused i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atigadda, Venkatram R., Xia, Gang, Desphande, Anil, Boerma, LeeAnn J., Lobo-Ruppert, Susan, Grubbs, Clinton J., Smith, Craig D., Brouillette, Wayne J., Muccio, Donald D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216212/ https://www.ncbi.nlm.nih.gov/pubmed/24801499 http://dx.doi.org/10.1021/jm5004792

Ejemplares similares

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts
por: Marayati, Raoud, et al.
Publicado: (2020)

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts
por: Williams, Adele P., et al.
Publicado: (2019)

Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis
por: Wu, Lizhi, et al.
Publicado: (2016)

Dataset on the response of Hut78 cells to novel rexinoids
por: Hackney Price, Jennifer, et al.
Publicado: (2018)

Oral retinoids and rexinoids in cutaneous T-cell lymphomas
por: Sokołowska-Wojdyło, Małgorzata, et al.
Publicado: (2013)

Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles
por: Marshall, Pamela A, et al.
Publicado: (2015)

Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics
por: Melo, Nathalia, et al.
Publicado: (2022)

The “Phantom Effect” of the Rexinoid LG100754: Structural and Functional Insights
por: Sato, Yoshiteru, et al.
Publicado: (2010)

Complex effects of rexinoids on ligand dependent activation or inhibition of the xenobiotic receptor, CAR
por: Tzameli, Iphigenia, et al.
Publicado: (2003)

Multi-Omics Approach to Dissect the Mechanisms of Rexinoid Signaling in Myoblast Differentiation
por: Khilji, Saadia, et al.
Publicado: (2021)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Moerland, Jessica A., et al.
Publicado: (2020)

The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer
por: Reich, Lyndsey A., et al.
Publicado: (2022)

Insights into interplay between rexinoid signaling and myogenic regulatory factor-associated chromatin state in myogenic differentiation
por: Hamed, Munerah, et al.
Publicado: (2017)

Melatonin and Its Metabolites Can Serve as Agonists on the Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor Gamma
por: Slominski, Andrzej T., et al.
Publicado: (2023)

Transcriptomic signature of Bexarotene (Rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models
por: Abba, Martin C, et al.
Publicado: (2008)

High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation
por: Gadd, Adam J.R., et al.
Publicado: (2018)

Activation of the μ‐opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure
por: Åstrand, Anna, et al.
Publicado: (2020)

PML–RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation
por: Kamashev, Dmitrii, et al.
Publicado: (2004)

Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Height, but not binding epitope, affects the potency of synthetic TCR agonists
por: Wilhelm, Kiera B., et al.
Publicado: (2021)

Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray
por: SEO, HYE-SOOK, et al.
Publicado: (2015)

Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency
por: Guzelj, Samo, et al.
Publicado: (2022)

Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and α4β7 Integrin and Direct Their Migration In Vitro
por: Manhas, Kavita R., et al.
Publicado: (2022)

Antimicrobial and Adjuvant Potencies of Di-n-alkyl Substituted Diazalariat Ethers
por: Patel, Mohit B., et al.
Publicado: (2023)

Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity
por: Beesu, Mallesh, et al.
Publicado: (2015)

Rewiring Tumor Cell State in Cancer Therapy: Comment on ‘9-cis-UAB30, a Novel Rexinoid Agonist, Decreases Tumorigenicity and Cancer Cell Stemness of Human Neuroblastoma Patient-Derived Xenografts’ by ‘Elizabeth Beierle et al.’
por: Chakraborty, Abhishek A.
Publicado: (2020)

Detection of 7-Dehydrocholesterol and Vitamin D3 Derivatives in Honey
por: Kim, Tae-Kang, et al.
Publicado: (2020)

Retinoid X Receptor Activation Prevents Diabetic Retinopathy in Murine Models
por: Dorofeeva, Iuliia, et al.
Publicado: (2023)

Retinoid X Receptor activation prevents diabetic retinopathy in murine models
por: Dorofeeva, Iuliia, et al.
Publicado: (2023)

Engineering Stem Cell Factor Ligands with Different c-Kit Agonistic Potencies
por: Tilayov, Tal, et al.
Publicado: (2020)

Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency – molecular profiling and functional rescue
por: Addis, L., et al.
Publicado: (2017)

Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis
por: Craft, Sam, et al.
Publicado: (2021)

A high potency nonformylated peptide agonist for the phagocyte N- formylpeptide chemotactic receptor
Publicado: (1994)

Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists
por: Azevedo Neto, Joaquim, et al.
Publicado: (2021)

Characterization of Potency of the P2Y13 Receptor Agonists: A Meta-Analysis
por: Dsouza, Chrisanne, et al.
Publicado: (2021)

Systematic Evaluation of the Metabolic to Mitogenic Potency Ratio for B10-Substituted Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2012)

A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency
por: Chodorge, M, et al.
Publicado: (2012)

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
por: Heckel, Franziska, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rj9huj0a3cklb61hvr629vul4s